Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Search Cook Medical

Peripheral Intervention
June 8th, 2017

FDA approves new indication for Zilver® PTX®


Zilver PTX, the world’s first drug-eluting stent for treating vascular disease in the superficial femoral artery, is now FDA-approved to treat total lesion lengths up to 300 mm per patient.

The previous indication was for total lesion lengths up to 140 mm per limb and 280 mm per patient. With a longer-length indication, endovascular therapists will now have more options for treating diseased vasculature.

Zilver PTX is indicated for improving luminal diameter for the treatment of de novo or restenotic symptomatic lesions in native vascular disease of the above-the-knee femoropopliteal arteries having reference vessel diameter from 4 mm to 7 mm and total lesion lengths up to 300 mm per patient.